Abstract
Therapeutic monoclonal antibodies are widely recognized to be a most promising means to treat an increasing number of human diseases, including cancers and autoimmunity. To a large extent, the efficacy of monoclonal antibody treatment is because IgG antibodies have greatly extended persistence in vivo. However, conventional rodent models do not mirror human antibody pharmacokinetics. The key molecule responsible for the extended persistence antibodies is the major histocompatibility complex class I family Fc receptor, FcRn. We describe human FcRn transgenic mouse models and how they can be exploited productively for the preclinical pharmacokinetic evaluation of therapeutic antibodies.
An erratum to this chapter is available at 10.1007/978-1-60761-058-8_24
An erratum to this chapter can be found at http://dx.doi.org/10.1007/978-1-60761-058-8_24
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Burnet, F. M., Freeman, M., Jackson, A. V. and Lush, D. (1941) The Production of Antibodies. Macmillan and Company Limited, Melbourne.
Simister, N. E. and Mostov, K. E. (1989) An Fc receptor structurally related to MHC class I antigens. Nature 337, 184–187.
Ahouse, J. J., Hagerman, C. L., Mittal, P., Gilbert, D. J., Copeland, N. G., Jenkins, N. A., et al. (1993) Mouse MHC class I-like Fc receptor encoded outside the MHC. J Immunol 151, 6076–6088.
Raghavan, M., Gastinel, L. N. and Bjorkman, P. J. (1993) The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release. Biochemistry 32, 8654–8660.
Burmeister, W. P., Gastinel, L. N., Simister, N. E., Blum, M. L. and Bjorkman, P. J. (1994) Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature 372, 336–343.
Burmeister, W. P., Huber, A. H. and Bjorkman, P. J. (1994) Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372, 379–383.
Roopenian, D. C. and Akilesh, S. (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7, 715–725.
Ghetie, V. and Ward, E. S. (2002) Transcytosis and catabolism of antibody. Immunol Res 25, 97–113.
Ghetie, V. and Ward, E. S. (1997) FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18, 592–598.
Deckert, P. M. (2009) Current constructs and targets in clinical development for antibody-based cancer therapy. Curr Drug Targets 10, 158–175.
Jarvis, B. and Faulds, D. (1999) Etanercept: a review of its use in rheumatoid arthritis. Drugs 57, 945–966.
Ober, R. J., Radu, C. G., Ghetie, V. and Ward, E. S. (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13, 1551–1559.
Presta, L. G. (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20, 460–470.
Liu, X. Y., Pop, L. M. and Vitetta, E. S. (2008) Engineering therapeutic monoclonal antibodies. Immunol Rev 222, 9–27.
Petkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Al Khabbaz, H., Brown, A. C., et al. (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18, 1759–1769.
Roopenian, D. C., Christianson, G. J., Sproule, T. J., Brown, A. C., Akilesh, S., Jung, N., et al. (2003) The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 170, 3528–3533.
Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., et al. (2003) The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 197, 315–322.
Anderson, C. L., Chaudhury, C., Kim, J., Bronson, C. L., Wani, M. A. and Mohanty, S. (2006) Perspective–FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 27, 343–348.
Osborn, B. L., Olsen, H. S., Nardelli, B., Murray, J. H., Zhou, J. X., Garcia, A., et al. (2002) Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303, 540–548.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Roopenian, D.C., Christianson, G.J., Sproule, T.J. (2010). Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies. In: Proetzel, G., Wiles, M. (eds) Mouse Models for Drug Discovery. Methods in Molecular Biology, vol 602. Humana Press. https://doi.org/10.1007/978-1-60761-058-8_6
Download citation
DOI: https://doi.org/10.1007/978-1-60761-058-8_6
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-057-1
Online ISBN: 978-1-60761-058-8
eBook Packages: Springer Protocols